How kidney failure affects drug levels in metastatic kidney cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at how chronic kidney failure changes the amount of certain cancer medicines in the blood. It involves people with metastatic clear cell kidney cancer who take pazopanib or cabozantinib, and compares drug levels in different kidney function groups.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have metastatic clear cell kidney cancer
- Be 18 or older
- Be able to do normal daily activities (ECOG 0–2)
- Currently being treated for metastatic kidney cancer with pazopanib or cabozantinib
- Match one of the kidney function groups (normal kidney function or chronic kidney disease stage 3–5, with or without dialysis)
- Be able to attend study visits and blood tests and follow the study plan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with kidney cancer that has spread to other parts of the body, who still have their original kidney tumor. If your cancer has responded very well to immunotherapy (a type of treatment that helps your immune system fight cancer), doctors want to see if removing the kidney tumor now can improve your outcome.
This trial studies how well cabozantinib works for advanced kidney cancer in people who are already receiving hemodialysis. It aims to see whether the treatment is effective and safe for this specific kidney function group.
This trial is testing a new treatment for people with advanced kidney cancer that has spread to other parts of the body. It aims to find a better way to manage the disease.
This study looks at genetic (RNA) testing of kidney cancer tissue to help choose the best drug treatment. It may help guide therapy for people with advanced or metastatic clear cell kidney cancer who are starting treatment for the first time.
This trial looks at how well cabozantinib works in people with advanced kidney cancer that has spread. It focuses on patients who had a quick response or a long response to the drug.
This trial tests whether tracking your symptoms with a digital app can help manage side effects while you receive two medications (cabozantinib and nivolumab) for advanced clear-cell kidney cancer that hasn't been treated before.
Hear when a new Kidney Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.